Hereditary Sensory Neuropathy Type 1 (HSN1) Overview
Learn About Hereditary Sensory Neuropathy Type 1 (HSN1)
- Hereditary sensory neuropathy type 1
- HSAN 1
- HSN1
- Hereditary sensory and autonomic neuropathy type 1
- Neuropathy hereditary sensory and autonomic type 1
- Neuropathy hereditary sensory radicular, autosomal dominant
University Of Alabama Health Services Foundation, PC
Eroboghene Ubogu is a Neurologist in Birmingham, Alabama. Dr. Ubogu and is rated as an Advanced provider by MediFind in the treatment of Hereditary Sensory Neuropathy Type 1 (HSN1). Their top areas of expertise are Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, Mitochondrial Complex 3 Deficiency, and Mitochondrial Complex 1 Deficiency. Dr. Ubogu is currently accepting new patients.
University Of Alabama Health Services Foundation, PC
Mohamed Kazamel is a Neurologist in Birmingham, Alabama. Dr. Kazamel and is rated as an Advanced provider by MediFind in the treatment of Hereditary Sensory Neuropathy Type 1 (HSN1). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Familial Dysautonomia, Chronic Inflammatory Demyelinating Polyneuropathy, and Primary Lateral Sclerosis. Dr. Kazamel is currently accepting new patients.
Lister Health Care Corporation
Sara Walker-Koziol is an Internal Medicine provider in Calera, Alabama. Dr. Walker-Koziol and is rated as an Experienced provider by MediFind in the treatment of Hereditary Sensory Neuropathy Type 1 (HSN1). Her top areas of expertise are Enlarged Liver, Vitamin B12 Deficiency, Glossitis, and Nephrosclerosis. Dr. Walker-Koziol is currently accepting new patients.
Summary: The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on the...
Summary: The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment. This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test ...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center